#OTC Markets Group - News

[probablyasocialecologist]

It’s a cartel in the classic economic and business sense—OPEC, not Sinaloa—a small group of connected actors working together to dominate a market that they only recently helped create. For crypto, where money is fake, value is purely hype-based, and new tokens can be spun out of nothing, it makes perfect sense. It’s a small industry, notionally worth $3 trillion at its peak in November 2021 but now hovering around $1 trillion. Many leading crypto luminaries know each other, interact on social media, trade with each other, and hobnob at small private gatherings like the Satoshi Roundtable, an annual invite-only meeting of select crypto insiders. Last spring, I confirmed via some attendees that Jean-Louis van der Velde, Tether’s elusive Hong Kong-based CEO, was at the invite-only FTX conference in the Bahamas, alongside luminaries like Bill Clinton and Tony Blair. In a public Twitter exchange, Bankman-Fried—whose Alameda hedge fund allegedly bought at least $36 billion worth of Tether in just a few years—said he didn’t know if van der Velde was there. I didn’t believe him. Many crypto power players have histories with poker, online gambling, offshore finance, and/or other gray-market economies. A lot of them do business via so-called OTC, or over the counter, trades: person-to-person exchanges that might not leave a trace on the blockchain, crypto’s supposedly transparent public ledger. Over time, the industry, including its black-market participants, has developed its own protocols, social codes, and, as interests aligned, what amounted to an omerta. What was good for one member was often good for the rest.

[sarahharmonbranding]

Product diffusion from the past -- Is it a bad sign that I've barely heard of these?

I really enjoyed this week's case, which covered the early product diffusion process of four offerings: a pre-packaged slice of peanut butter, a silver-lined bandage, Sirius/XM radios, and an "odor printer". I was struck by the absurdity of most of these offerings, despite the very real coverage they earned at the time, and the fact that with the exception of one, I'd never even heard of them. The case asked for our ranked analysis of which products will diffuse most quickly/broadly. Here are my thoughts:

Sirus/XM radio. While known to me as a single entity, Sirius and XM were once competitors in the emerging pay-for-radio space. The business case is clear: commuters and drivers who spend significant time in their car each day were unsatisfied with the unreliable, ad-riddled, and un-customizable radio experience. Sirius/XM had insight into their customer base, size, and could estimate who was willing to pay for more targeted, high quality content. Pair this with a deal to offer the service with car purchases from GM, Ford, and Chrysler, and you've removed significant barriers for customers to adopt the product. No wonder this is the only offering I've heard of.

Westaim Biomedical silver bandages. As someone who grew up in the small town of Exeter, NH I was excited to see a company from Exeter represented in the case. The bad news: I, nor my friends or family, have ever heard of it. However, that does not mean it was all bad for Westaim. While anecdotally it seems the silver bandages did not reach OTC consumer appeal, the company had insight into its addressable market and proven efficacy in medical applications like chronic wounds. My guess is that the patent was acquired or is maybe used in more specialized hospital settings today, which is still a relative win for diffusion.

Pre-packaged slice of peanut butter. This offering feels like nothing more than a spoof food item, and I doubt it had mass diffusion in the consumer market. On the plus side, the company did appear to try and solve a problem faced by its consumers (peanut butter pulled on soft bread when making a PB&J) and thus had a better chance of diffusion than one less researched. While I believe society is always looking for a shortcut, this might be one step too far and too unnecessary. Maybe the better product is the R&D put into non-stick packaging--now THAT could be useful in several applications.

"Odor spray/printer". This idea was both ridiculous and broad. Who were they appealing to? The article mentioned "foodies", or people with a heightened appreciation for the value of good smell, but overall the product strategy felt directionless and unattainable. Seeing as I've never heard of such a thing, I imagine this idea died before there was even a product to test.

Doing these types of thought exercises has been valuable as my Branding group thinks about our project addressing Peloton. Peloton has most likely reached its peak diffusion when it comes to its hardware bike. Peloton now has to re-brand to diffuse a new product offering, its fitness software, and gauge a whole new group of customers for potential adoption. This won't be easy, as YouTube, Instagram, TikTok, and even gyms have begun offering similar content.

[xtruss]

FDA Proposes Ending Use of Oral Phenylephrine as OTC Monograph Nasal Decongestant Active Ingredient After Extensive Review

— November 07, 2024 | FDA Press Release

A bottle of Vicks DayQuil cold and flu medicine containing phenylephrine is displayed for sale in a CVS Pharmacy store in Hawthorne, California, on Sept. 12, 2023. Patrick T. Fallon | AFP | Getty Images

Key Points:

The Food and Drug Administration proposed ending the use of a common ingredient in many popular over-the-counter cold and allergy medications because it doesn't actually relieve nasal congestion.

The FDA said the proposed order is not final yet, which means companies can still market over-the-counter drugs containing oral phenylephrine for now.

A final order will force pharmacies to clear shelves of hundreds of products containing oral forms of the ingredient, which is found in versions of drugs such as NyQuil, Benadryl, Sudafed and Mucinex.

Today, the U.S. Food and Drug Administration announced it is proposing to remove oral phenylephrine as an active ingredient that can be used in over-the-counter (OTC) monograph drug products for the temporary relief of nasal congestion after an agency review of the available data determined that oral phenylephrine is not effective for this use. For now, companies may continue to market OTC monograph drug products containing oral phenylephrine as a nasal decongestant. This is a proposed order. Only a final order will affect what products can be marketed. The proposed order is based on effectiveness concerns, not on safety concerns.

Currently, oral phenylephrine is widely used as a nasal decongestant active ingredient in many OTC monograph drug products. It is important to note that some products only contain oral phenylephrine as a single, active ingredient. Others contain oral phenylephrine and another active ingredient (e.g., acetaminophen or dextromethorphan), and the presence of oral phenylephrine in these medicines does not affect how other active ingredients work to treat the symptoms for which they are intended.

“It is the FDA’s role to ensure that drugs are safe and effective,” said Patrizia Cavazzoni, M.D., director of the FDA’s Center for Drug Evaluation and Research (CDER). “Based on our review of available data, and consistent with the advice of the advisory committee, we are taking this next step in the process to propose removing oral phenylephrine because it is not effective as a nasal decongestant.”

The agency conducted a comprehensive review of all available data on the safety and efficacy of oral phenylephrine, including the historical data that were used to support the determination made 30 years ago that oral phenylephrine was effective as a nasal decongestant, as well as newer clinical data on oral phenylephrine that have since become available.

Last fall, the FDA also held a Nonprescription Drug Advisory Committee meeting to discuss the ‘Generally Recognized as Safe and Effective’ (GRASE) status of oral phenylephrine as a nasal decongestant. The committee discussed new data on the effectiveness of orally administered phenylephrine and unanimously concluded that the current scientific data do not support that the recommended dosage in the OTC cold, cough, allergy, bronchodilator and antiasthmatic drug products monograph for orally administered phenylephrine’s effectiveness as a nasal decongestant.

“Consumers should know that a range of safe and effective drugs and other treatments is available to temporarily relieve congestion symptoms due to allergies or a common cold,” said Theresa Michele, M.D., director of the Office of Nonprescription Drug Products in CDER. “Consumers can also talk to their doctor or pharmacist about ways to treat these symptoms.”

Over the counter cold and flu medicine, NyQuil, DayQuil, Mucinex on the shelf. (Jeffrey Greenberg/Universal Images Group via Getty Images)

Because a variety of different drug products may be sold under the same brand name, consumers should always read the Drug Facts label to determine which ingredients are in a medication, and to be aware of important warnings and directions for use. Phenylephrine is also an ingredient in nasal sprays to treat congestion. The FDA’s action is only related to orally administered phenylephrine and not the nasal spray form.

The FDA is seeking public comments on this proposed order. Instructions on how to submit comments are found in the proposed order available on OTC Monographs@FDA. If, after considering the comments, the FDA concludes oral phenylephrine is not effective as a nasal decongestant, the FDA will issue a final order removing oral phenylephrine from the OTC monograph, and drug products thereafter could no longer contain oral phenylephrine as a nasal decongestant. The FDA would provide manufacturers with appropriate time to either reformulate drugs containing oral phenylephrine or remove such drugs from the market.

Sudafed and other common nasal decongestants containing pseudoephedrine are on display behind the counter at Hospital Discount Pharmacy in Edmond, Okla., Jan. 11, 2005. On Tuesday, Sept. 12, 2023 advisers to the Food and Drug Administration said that a different ingredient, phenylephrine, is ineffective at relieving nasal congestion. Drugmakers reformulated their products with phenylephrine after a 2006 law required pseudoephedrine-containing medications be sold from the behind pharmacy counter. (AP Photo, File)

— The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products.

[cryptoroadmap247]

Goats Airdrop Listing & Withdraw Confirm | GOATS Pre-Market OTC Live on ...

$GOATS Pre-Market OTC Trading will be Live on #Gateio Soon! 🐐🪙 ⏰ Trading starts: 08:00 AM Nov 6th, 2024 (UTC)

⚠️ Less than 6 HOURS left till the GOATS Halloween Fes: CANDY IN - $TON OUT wraps up! ⚠️

Time’s running out to grind and spend every last bit of that Candy! 🍬💸

Remember: use it all, stack it all — over 5+ $TON rewards up for grabs! 💰

Jump in NOW or miss out big time for $TON and $GOATS!

🚀 Less than 2 days left to take advantage of the GOATS to Glory boost!

The $GOATS TGE is so close you can feel it! Time to grind hard and claim every $GOATS you can.

Every move counts – don’t miss your shot to maximize gains for

The GOATS airdrop on Telegram is a marketing campaign designed to introduce and distribute GOATS tokens to the user community. By leveraging Telegram as a platform, this airdrop aims to expand GOATS' user base, increase interaction in the community, and encourage token adoption. In this airdrop program, participants are usually asked to follow a number of steps such as:

1. Join the GOATS Official Telegram Channel or Group - Participants are required to become members of the group or channel to receive important announcements and follow the latest developments.

2. Fill out the Registration Form - This form usually includes basic information as well as related social media account details, such as a Twitter account or crypto wallet.

3. Perform Social Media Tasks - Often participants are asked to perform certain tasks such as retweeting, liking, or sharing official GOATS content on Twitter or other platforms. This helps expand the reach of GOATS promotions organically.

4. Refer a Friend - Some airdrops provide additional tokens if participants invite friends to join via a referral link, further encouraging the spread of tokens to the wider community. Tokens distributed via this airdrop are usually given after all tasks are fulfilled and verified by the GOATS team. The number of tokens received varies, depending on the distribution scheme that has been established, as well as the level of participation of each participant. These airdrops are often an opportunity for users to collect new tokens before they are officially listed on an exchange, which can provide potential profits if the value of the token increases after listing.

GOATS has quickly gained attention in the meme coin space, amassing a significant following. With its innovative Telegram mini-app and viral appeal, GOATS is preparing for a major airdrop event. If you’re looking to capitalize on this airdrop and claim your free GOATS tokens, it’s essential to understand what GOATS is, the eligibility criteria, and how to participate. $GOATS is rapidly gaining traction as a popular Telegram mini-app, attracting millions of active users, alongside the buzz and success of other Telegram-based games like Hamster Kombat, X Empire, and Blum.

Read: Top Telegram tap-to-earn games

What is GOATS Token? GOATS Token is a rising meme coin that has rapidly gained traction within the crypto community. It positions itself as more than just a meme coin by offering a unique utility within the Telegram ecosystem. Through its Telegram mini-app, GOATS allows users to interact with their tokens directly on the platform, enhancing accessibility and user engagement.

One of the most talked-about events in the GOATS ecosystem is the GOATS Airdrop—a strategic initiative aimed at expanding its user base and distributing tokens to loyal and new participants. With over 20 million users already engaged, the airdrop is anticipated to be one of the largest in the meme coin market amid the ongoing memecoin supercycle. The GOATS airdrop listing date is eagerly awaited by users keen to capitalize on this opportunity.

Read: Top memecoins 2024

GOATS Airdrop Eligibility Criteria The GOATS team has set specific eligibility criteria for participants to ensure a fair and balanced distribution of tokens. Here are the key factors that determine who is eligible for the airdrop:

Telegram Mini-App Engagement: GOATS’ airdrop is primarily based around its Telegram mini-app. To qualify for the airdrop, users must be actively engaged with the GOATS Telegram app. This includes creating an account within the app and completing tasks such as joining groups, participating in community activities, and referring friends to the app. Holding a Minimum Number of GOATS Tokens: Some eligibility criteria revolve around holding a minimum number of GOATS tokens in your wallet. This requirement ensures that early supporters and holders of GOATS tokens are rewarded for their loyalty to the project. Make sure to check the Telegram GOATS listing date for the official token requirements before participating. Referral Programs: GOATS emphasizes community participation, and one way to increase your airdrop allocation is through referrals. By inviting friends to join the Telegram GOATS mini-app, users can boost their eligibility and potentially claim more tokens. Keep an eye on GOATS airdrop new date announcements for additional referral opportunities. Active Social Media Participation: GOATS often hosts social media campaigns where users can gain extra tokens by sharing content, using specific hashtags, or creating memes about the GOATS ecosystem. Being active on platforms like Twitter and participating in official campaigns can increase your airdrop rewards. How to Claim GOATS Airdrop Once you have confirmed your eligibility, the next step is to claim your tokens. Follow these steps to ensure you can successfully claim the GOATS airdrop:

Sign Up for the GOATS Telegram Mini-App: Start by signing up for the GOATS mini-app within Telegram. This will be your central hub for interacting with the GOATS ecosystem, checking your token balance, and receiving airdrop notifications. Complete the Necessary Tasks: Make sure you fulfill all the eligibility criteria, including holding the minimum number of tokens, completing KYC, and participating in community activities. Check for official updates on the GOATS airdrop new date to ensure you don’t miss any deadlines. Monitor the Airdrop Listing Date: The official GOATS airdrop listing date will be announced via the Telegram mini-app and other official channels. Once the airdrop is live, eligible users will receive their tokens automatically in their wallets. Keep track of updates, especially on Twitter and other GOATS community channels, for real-time information. We will be updating this article as well, so keep an eye out on this space as well! Claim Your Tokens: When the airdrop begins, eligible users will receive a notification within the Telegram app to claim their GOATS tokens. Simply follow the on-screen instructions to transfer the airdropped tokens into your wallet. Stay Updated for Future Airdrops: GOATS is expected to roll out more airdrop campaigns as it progresses toward its listing date. Following their social channels will ensure you’re always in the loop for upcoming events and potential bonus tokens. Conclusion The GOATS airdrop represents a major opportunity for early adopters and active community members to earn free tokens and get involved in the future of this rapidly growing meme coin. By meeting the eligibility criteria and staying engaged with the Telegram app, you can easily claim your share of the GOATS airdrop. With the official GOATS airdrop listing date approaching, now is the perfect time to prepare and maximize your potential earnings. Stay tuned for the latest updates on the GOATS project and its progress toward becoming a major player in the crypto market.

This detailed guide ensures that you don’t miss out on claiming your free GOATS tokens and participating in the next phase of its exciting journey.

[chemistwarehouse2]

Chemist Warehouse: A Leader in Australian Retail Pharmacy

Chemist Warehouse is one of Australia's most recognizable names in retail pharmacy, often referred to as "Australia’s Cheapest Chemist." With over 500 stores across Australia, New Zealand, and even some expansion into China, Chemist Warehouse has become a household name synonymous with affordable healthcare, prescription medications, and a wide variety of consumer goods.

Origins and Growth Chemist Warehouse was founded in 2000 by Mario Verrocchi and Jack Gance, building on their vision of offering customers competitive prices on pharmaceutical products. Unlike traditional pharmacies that focus more on providing personal service, Chemist Warehouse adopted a high-volume, low-cost model that allowed them to offer substantial discounts on products ranging from prescription medications to everyday essentials like skincare, supplements, and baby care items.

This business model has proven incredibly successful. The company's rapid expansion was driven by their ability to offer prices lower than traditional pharmacies, often by as much as 50%. Chemist Warehouse has capitalized on bulk purchasing and streamlined operations, passing on these savings to consumers.

Pricing and Accessibility The affordability of Chemist Warehouse products has been a key driver of its success. Consumers looking for over-the-counter medications, beauty products, vitamins, and even fragrances often find Chemist Warehouse as the go-to destination. Their slogan, "Why Pay More?", resonates strongly in an environment where healthcare costs can be significant.

Chemist Warehouse is also known for running regular sales and promotions, further driving customer loyalty. The company’s online store has expanded its reach beyond the physical outlets, offering customers the convenience of shopping from home and receiving their orders delivered.

Product Range and Services In addition to pharmaceuticals, Chemist Warehouse stocks an extensive range of health and wellness products, making it a one-stop shop for many consumers. Some key product categories include:

Prescription Medications: As a licensed pharmacy, Chemist Warehouse offers all major prescription drugs at highly competitive prices. Over-the-Counter Medications: The company sells a variety of OTC medications, including pain relief, cold and flu treatments, and allergy medications. Health Supplements: Customers can find a broad range of vitamins, minerals, and herbal supplements. Beauty and Skincare: Chemist Warehouse carries a vast selection of beauty products, including popular skincare brands, cosmetics, and personal care items. Fragrances: One of the unexpected areas of growth for Chemist Warehouse has been its range of discount fragrances, appealing to consumers looking for affordable luxury. Apart from product variety, the stores also provide pharmaceutical services like prescription refills, health checks, and consultations, ensuring that customers receive professional healthcare advice alongside their purchases.

Online Presence and International Expansion Chemist Warehouse’s e-commerce platform has played a critical role in its business strategy, offering customers nationwide access to its wide product range. The brand’s click-and-collect service allows customers to order online and pick up in-store, adding to its convenience.

In addition to its dominance in Australia, Chemist Warehouse has expanded internationally, with stores in New Zealand and early ventures into China through partnerships and online marketplaces like Alibaba’s Tmall Global. This international expansion has allowed Chemist Warehouse to tap into the growing demand for trusted Australian health products in overseas markets, especially in Asia, where Australian-made goods are highly regarded for their quality.

Challenges and Criticism Despite its success, Chemist Warehouse has faced its share of challenges. The company has been criticized by smaller pharmacies and industry groups for undercutting prices and monopolizing the market. Some argue that its aggressive pricing strategy has put immense pressure on independent pharmacies, making it difficult for them to compete.

There have also been labor-related disputes, with some employees raising concerns about working conditions and wages. However, Chemist Warehouse has made efforts to address these issues over time.

The Future of Chemist Warehouse Chemist Warehouse continues to evolve, with plans for further growth both domestically and internationally. The company has adapted to changing consumer behaviors, particularly with the rise of online shopping, and remains at the forefront of retail pharmacy innovation.

With a focus on affordable healthcare, a broad product offering, and the ability to adapt to market demands, Chemist Warehouse is likely to remain a dominant force in the retail pharmacy industry for years to come.

Conclusion Chemist Warehouse has revolutionized the pharmacy industry in Australia by combining affordability, accessibility, and convenience. Its aggressive pricing model has not only disrupted the market but also provided significant benefits to consumers, making healthcare and everyday essentials more affordable for millions of people.

While it faces competition and criticism, Chemist Warehouse continues to thrive, expanding its influence in both physical and digital retail spaces. The company’s commitment to providing value for money ensures that it will remain a trusted name in Australian homes and beyond.

[industryforecastnews]

Rheumatoid Arthritis Therapeutics Market To Reach USD 36.39 Billion By 2030

Rheumatoid Arthritis Therapeutics Market Growth & Trends

The global rheumatoid arthritis therapeutics market size is expected to reach USD 36.39 billion by 2030, expanding at a CAGR of 5.93% from 2024 to 2030, according to a new study by Grand View Research, Inc. Some of the key trends driving the market are availability of novel biologics, increase in potential clinical pipeline candidates, and rise in aging population. Thus, growing availability and awareness of safer drugs are projected to escalate rheumatoid arthritis drugs market growth. 

Rheumatoid arthritis affects approximately 1% of the global population. The condition has different symptoms such as joint pain, swelling, and stiffness, which are generally accompanied by chronic pain and inability to perform daily activities. Over a prolonged period, this disorder can hamper a patient’s mobility and can lead to permanent joint damage. If left untreated, this disorder can lead to mobility impairment and risk of joint replacement.

Growing prevalence of the disease, presence of biologics & biosimilars, and well-defined regulatory guidelines are poised to provide a fillip to the market. According to the Arthritis Foundation, 64% of the population within the age group of 65 is likely to suffer from arthritis in U.S. Increasing awareness regarding disease remittance therapies and rising healthcare expenditure in developed regions are estimated to promote revenue growth.

Current treatment for rheumatoid arthritis includes generic pharmaceuticals such as NSAIDs and corticosteroids along with novel biologics such as JAK inhibitors and IL-6 antagonists, which are widely used in developed countries due to their high effectiveness. New product launches such as Infliximab and Adalimumab biosimilars are anticipated to work in favor of the market. Moreover, Eli Lilly’s Olumiant and AbbVie’s Upadacitinib are expected to cut down chances of disease remittance.

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/rheumatoid-arthritis-therapeutics-market

Rheumatoid Arthritis Therapeutics Market Report Highlights

Biopharmaceuticals segment led the market and accounted for 88.73% of the global revenue in 2023. Biopharmaceuticals are large-molecule drugs that are manufactured, extracted, and synthesized from biological sources.

Prescription led the market with a market share of 89.64% in 2023. As rheumatologist consultations rise, the prescription segment is expected to remain dominant in the market for rheumatoid arthritis medications over the forecast period.

North America rheumatoid arthritis therapeutics market accounted for 52.31% share in 2023. The regional market continues to grow and evolve, driven by demographic shifts, advancements in medical research, regulatory changes, and an increasing emphasis on personalized healthcare.

The Asia Pacific rheumatoid arthritis therapeutics market is experiencing significant growth, driven by the increasing prevalence of rheumatoid arthritis, improving healthcare infrastructure, and advancements in treatment options.

Rheumatoid Arthritis Therapeutics Market Segmentation

Grand View Research has segmented global rheumatoid arthritis therapeutics market report based on molecule, sales channel, and region:

Rheumatoid Arthritis Therapeutics Molecule Outlook (Revenue, USD Million, 2018 - 2030)

Pharmaceuticals

NSAIDs

Analgesics

DMARDs

Glucocorticoids

Biopharmaceuticals

Biologics

TNF-α antagonists

T-cell inhibitors

CD20 antigen

JAK inhibitors

anti-IL6 biologics

Biosimilars

CD20 antigen

TNF-α antagonists

Rheumatoid Arthritis Therapeutics Sales Channel Outlook (Revenue, USD Million, 2018 - 2030)

Prescription

Over-the-Counter (OTC)

Regional Insights

North America rheumatoid arthritis therapeutics market accounted for 52.31% share in 2023.The regional market continues to grow and evolve, driven by demographic shifts, advancements in medical research, regulatory changes, and an increasing emphasis on personalized healthcare. The aging population across the region significantly impacts the demand for rheumatoid arthritis therapeutics. As people live longer, the prevalence of chronic conditions such as RA increases, boosting the need for effective treatment options. This demographic trend is a primary driver of sustained market growth.

Europe Rheumatoid Arthritis Therapeutics Market Trends

The Europe rheumatoid arthritis therapeutics market is substantially changing, influenced by healthcare reforms, research advancements, and patient-focused initiatives across different countries. The prevalence of rheumatoid arthritis is increasing due to an aging population and changing lifestyles, leading to a growing demand for effective & innovative treatment options across the continent.

Asia Pacific Rheumatoid Arthritis Therapeutics Market Trends

The Asia Pacific rheumatoid arthritis therapeutics market is experiencing significant growth, driven by the increasing prevalence of rheumatoid arthritis, improving healthcare infrastructure, and advancements in treatment options. The prevalence of rheumatoid arthritis is on the rise across Asia Pacific due to factors such as the aging population, changing lifestyles, and increasing awareness leading to early diagnosis. This rising prevalence has led to a growing demand for effective and affordable RA treatments, prompting healthcare providers & policymakers to focus on improving RA care & management.

List of Key Players of Rheumatoid Arthritis Therapeutics Market

AbbVie, Inc.

Boehringer Ingelheim International GmbH

Novartis AG

Regeneron Pharmaceuticals Inc.

Pfizer, Inc.

Bristol-Myers Squibb Company

F. Hoffmann-La Roche Ltd.

UCB S.A.

Johnson & Johnson Services, Inc.

Amgen, Inc.

Lilly (Eli Lilly and Company)

Browse Full Report: https://www.grandviewresearch.com/industry-analysis/rheumatoid-arthritis-therapeutics-market

[nphealthcare24]

Empowering Your Healthcare Vision: Partner with NP Healthcare for a Lucrative PCD Pharma Franchise in India

NP Healthcare stands apart as a main PCD (Propaganda cum Distribution) Pharma Franchise company in India.We offer an extraordinary chance for business visionaries and laid out organizations to flourish in the unique Indian drug market. Here's the reason NP Medical care ought to be your accomplice of decision:

Unmatched Quality and Product Portfolio:

Unflinching Obligation to Greatness: We focus on the prosperity of patients by assembling and dispersing first class drug items across different remedial portions. Our severe adherence to WHO and GMP rules guarantees the greatest norms.

Various Item Reach: We take care of an extensive variety of medical services needs with a broad portfolio incorporating:

Professionally prescribed drugs

Over-the-counter (OTC) drugs

Nutraceuticals

Topical formulations

Building Your Success: A Supportive Ecosystem

Exclusive Monopoly Rights: NP Healthcare empowers its franchise partners with exclusive monopoly rights in designated territories. This kills contest from other NP Medical care establishments, permitting you to construct areas of strength for a presence and boost benefit.

Worthwhile Overall revenues: We offer serious net revenues on our items, guaranteeing a solid profit from your venture. Our evaluating procedure offsets moderateness for customers with your procuring potential.

Comprehensive Marketing & Promotional Support: We understand the importance of effective marketing. We provide extensive support with:

Free physician samples to encourage product adoption

A range of marketing materials like MR bags, visual aids, and promotional tools

Regular training programs to enhance your sales and marketing skills

A Tradition of Trust and Organization

Moral Strategic policies: Respectability shapes the foundation of our business reasoning. We put stock in straightforward dealings and fair associations.

Devoted Client assistance: Our group is focused on offering remarkable help to our establishment accomplices. We offer brief help with inquiries, request handling, and coordinated factors.

Cooperative Development: We view our establishment accomplices as an augmentation of the NP Medical services family. We cooperate to accomplish shared objectives and guarantee the progress of your business.

Putting resources into Your Future with NP Healthcare

By partnering with NP Healthcare, you gain access to:

A Renowned Brand: We have established a strong reputation for quality and reliability in the Indian pharmaceutical sector. This memorability means an upper hand for your business.

Experienced Initiative: Our group involves industry veterans with a demonstrated history of progress. We influence their skill to guide and support your development process.

Continuous Innovation: NP Healthcare is committed to ongoing research and development. We strive to introduce new and effective products to cater to evolving healthcare needs.

Taking the Next Step

NP Healthcare offers a compelling opportunity to build a rewarding career in the Indian pharmaceutical landscape. If you're a passionate entrepreneur or a business seeking expansion, we invite you to explore our Best PCD Pharma Franchise Company in India.

Contact us today to schedule a consultation and learn more about how NP Healthcare can empower your vision for a successful and impactful healthcare business.

[atomxmedia]

CoinDCX Prime Launched For High Net Worth Individuals Targeting $100 Million AUM By FY25

CoinDCX, a renowned Indian cryptocurrency exchange, has announced a new project known as CoinDCX Prime. This program is designed exclusively for High-Net-Worth Individuals (HNIs), family offices, and institutional investors, providing them with a specialized approach to cryptocurrency trading. The debut comes at a time when the Indian crypto industry is seeing an increase in engagement from these categories.

Tailored Solutions for Sophisticated Investors

CoinDCX Prime goes beyond the standard trading experience offered by CoinDCX’s core platform. It provides a dedicated service layer designed to meet the specific needs of high-volume investors. Here’s a breakdown of what CoinDCX Prime offers:

Minimum Investment Threshold: CoinDCX Prime caters to investors with a minimum portfolio size of Rs. 50 Lakhs ($62,500 USD). This ensures a focus on experienced investors with a deeper understanding of the cryptocurrency market.

Personalized Investment Strategies: Prime members gain access to personalized investment solutions crafted by experienced financial advisors. These solutions consider individual risk appetites and long-term investment goals.

Dedicated Account Management: CoinDCX Prime assigns seasoned key account managers to each member. These dedicated professionals provide ongoing support, guidance, and market insights tailored to individual investment journeys.

Building on Existing Offerings

CoinDCX Prime builds upon the existing suite of services offered by CoinDCX. Prime members still benefit from features available to all users, such as:

VIP Program: This program offers tiered discounts on trading fees based on trading volume.

Over-the-Counter (OTC) Desk: This service facilitates large-volume trades executed directly between CoinDCX and institutional investors.

Catering to Growing Demand

Minal Thukral, Head of Strategy and Growth at CoinDCX, emphasizes the growing interest from HNIs and institutions: “Over 1.5 crore [15 million] Indian investors trust CoinDCX with their cryptocurrency adventure. We’re happy to see the same degree of trust and interest from HNIs. We’ve already onboarded over 100 institutional investors, 2,500+ high-net-worth clients, and served over 25 family offices. There is high demand from this group of investors, which is why we are offering Prime Services.

Read more: Marketing News, Advertising News, PR and Finance News, Digital News

[stock-trend]

Exploring Penny Stocks - Opportunities and Risks in the World of Low-Priced Shares

Penny stocks, often referred to as "micro-cap" or "nano-cap" <a href="https://stocktrend.in/">stocks,</a> are shares of small companies that trade at low prices, typically below $5 per share. While these stocks may seem enticing due to their low cost and potential for high returns, they also carry significant risks. In this article, we'll delve into the world of penny stocks, exploring their opportunities, risks, and key considerations for investors.

Understanding Penny Stocks: Penny stocks are issued by companies with small market capitalizations, often in emerging industries or sectors. These companies may have limited operating histories, minimal assets, and higher-than-average business risks. As a result, penny stocks tend to be more volatile and speculative than shares of larger, more established companies.

Opportunities in Penny Stocks:

Potential for High Returns: One of the primary attractions of penny stocks is their potential for rapid price appreciation. Since these stocks trade at low prices, even a small increase in share price can result in significant percentage gains for investors.

Early Entry into Emerging Industries: Penny stocks often represent companies in emerging industries or niche markets. Investing in these stocks allows investors to gain exposure to potentially high-growth sectors before they become mainstream.

Diversification: Including penny stocks in a diversified investment portfolio can provide additional opportunities for growth and diversification. However, it's essential to allocate only a small portion of your portfolio to these high-risk investments.

Risks Associated with Penny Stocks:

Lack of Liquidity: Penny stocks typically trade on over-the-counter (OTC) markets or smaller stock exchanges with lower trading volumes. As a result, they may lack liquidity, making it challenging to buy or sell shares at desired prices.

Limited Information and Transparency: Many penny stock companies have limited financial reporting requirements and may not provide comprehensive information to investors. This lack of transparency can make it difficult for investors to assess the true value and prospects of these companies.

Higher Risk of Fraud and Manipulation: The low price and volatility of penny stocks make them susceptible to manipulation by unscrupulous individuals or groups. Pump-and-dump schemes, where promoters artificially inflate the price of a stock before selling their shares, are common in the penny stock market.

Business Risk: Penny stock companies are often small and may lack the resources or experience to navigate challenging market conditions. They may also face regulatory hurdles, competitive pressures, or technological disruptions that could jeopardize their future prospects.

Key Considerations for Investors:

Conduct Thorough Research: Before investing in penny stocks, thoroughly research the companies, industries, and market dynamics. Look for companies with strong fundamentals, sustainable business models, and transparent management teams.

Manage Risk: Only invest money in penny stocks that you can afford to lose. Due to their speculative nature, penny stocks should be considered high-risk investments and should only constitute a small portion of your overall investment portfolio.

Stay Informed: Stay informed about market developments, regulatory changes, and company-specific news that could impact the performance of penny stocks. Regularly monitor your investments and be prepared to adjust your strategy as needed.

Avoid Herd Mentality: Avoid following the herd or chasing hot penny stocks based on speculation or hype. Instead, focus on investing in companies with solid fundamentals and long-term growth potential.

[clfcoin]

How CLFCOIN Breaks Out as the Crypto Market Breaks Down

How CLFCOIN Breaks Out as the Crypto Market Breaks Down

In this rapidly evolving digital age, crypto have transformed from a fringe investment option to an important part of the mainstream financial market. As more individual and institutional investors enter this market, choosing a reliable, secure and user-friendly crypto exchange becomes crucial. With so many options to choose from, CLFCOIN Exchange strives to be your trusted crypto trading platform.

Our Mission

Our mission is to provide a secure, transparent, and easy-to-use platform that makes it easy for everyone to access and trade crypto. Whether you are new to the crypto market or an experienced investor, we are committed to providing you with the best possible trading experience.

Security and compliance: Our top priority

At our exchange, security is always a top priority. We employ industry-leading security measures, including multi-signature wallets, comprehensive internal controls and regular security audits to ensure the safety of your assets and personal information. At the same time, we strictly adhere to the regulations of U.S. and international financial regulators to ensure a compliant trading environment for our clients.

User experience: Simple, intuitive, seamless

We understand that complex trading interfaces and slow user experiences can be a turn-off for investors. Therefore, we have designed an intuitive trading platform that is easy to navigate regardless of your experience. With support for one-click buying and selling, real-time market data, customized price alerts and comprehensive educational resources, our platform is designed to make the trading process as simple and efficient as possible.

Products and services: For all your needs

We offer a wide range of crypto trading pairs, covering from the most well-known Bitcoin and Ether to the latest tokens. In addition to regular buying and selling services, we also offer advanced trading features such as future trading, leverage trading and OTC trading services to meet the needs of different investors. We aim to be your one-stop crypto trading solution.

Community and support: We are here for you!

Building a community of support and education is vital to us. We offer 24/7 customer service, and our team of experts is here to support you no matter what questions you have or how much help you need. In addition, we offer regular seminars and online courses to help you understand the market dynamics and improve your trading skills.

Future Outlook

We are at the forefront of innovation in crypto and blockchain technology. As this industry continues to evolve, we are committed to continue investing in technological innovation and customer services to ensure that our exchange not only meet your needs today, but also welcome the challenges of tomorrow.

Social Responsibility

We are committed to being a socially responsible enterprise, and have helped many people in need since its inception. Every year, we cooperate with individuals and groups concerned about charity to promote charity in order to promote social responsibility.

In this market full of opportunities and challenges, choosing the right exchange is the key to success. We believe that with our relentless pursuit of security, user experience and service, we can be your reliable partner in exploring the infinite possibilities of the crypto world together. We welcome you to join CLFCOIN and start a new chapter of crypto investment together.

[shubhamman2376]

How Tata Capital Unlisted Shares Can Drive Growth in Your Investment Portfolio

An Overview of Tata Capital

Tata Capital is a renowned financial services company in India. Established in 2007, it is a subsidiary of Tata Sons Limited, the holding company of the Tata Group. Tata Capital offers a wide range of financial products and services, including loans, investments, and insurance.

With a strong reputation and a track record of delivering quality services, Tata Capital has become a trusted name in the financial sector. The company has a robust presence across various domains, including retail finance, commercial finance, wealth management, and infrastructure finance.

The Growth Potential of Tata Capital Unlisted Shares

Investing in unlisted shares of companies like Tata Capital can offer significant growth potential. Unlisted shares are stocks of companies that are not listed on any stock exchange but are traded in the over-the-counter (OTC) market. These shares can provide investors with unique opportunities to generate substantial returns.

Tata Capital, being a part of the esteemed Tata Group, has inherent growth potential. The Tata Group has a diversified presence across sectors such as automobiles, steel, information technology, and consumer goods, which adds to the stability and growth prospects of Tata Capital.

Investing in Tata Capital unlisted shares allows investors to tap into the growth potential of the company before it goes public. As the company expands its business and achieves new milestones, its unlisted shares' value can be appreciated significantly, leading to substantial capital gains for investors.

Analyzing the Tata Capital Share Price

Understanding the share price of Tata Capital is crucial for investors looking to invest in its unlisted shares. The share price reflects the market's perception of the company's value and growth prospects.

While Tata Capital is not publicly listed, the share price can still be estimated based on various factors such as the company's financial performance, industry trends, and market sentiment. Investors can analyze the financial statements, earnings reports, and other relevant information to assess the intrinsic value of Tata Capital shares.

It is important to note that investing in unlisted shares comes with certain risks. The lack of liquidity and transparency associated with unlisted shares can make it challenging to determine the fair value of the shares. Therefore, it is advisable to consult with financial experts or conduct thorough research before making any investment decisions.

Factors to Consider Before Investing in Tata Capital Unlisted Shares

Investing in unlisted shares requires careful consideration of various factors. Here are some key factors to keep in mind before investing in Tata Capital unlisted shares:

Financial Performance: Evaluate Tata Capital's financial performance, including revenue growth, profitability, and debt levels. A company with a strong financial position is more likely to generate higher returns for investors.

Industry Analysis: Analyze the industry in which Tata Capital operates. Consider factors such as market dynamics, competitive landscape, and regulatory environment. A favorable industry outlook can boost the growth prospects of the company and its unlisted shares.

Management Expertise: Assess the management team of Tata Capital. Look for experienced professionals with a proven track record in the financial services industry. A competent management team is crucial for the long-term success of the company.

Risk Assessment: Evaluate the risks associated with investing in Tata Capital unlisted shares. Consider factors such as market volatility, economic conditions, and regulatory changes. Diversifying your investment portfolio can mitigate these risks.

Benefits of Investing in Unlisted Shares

Investing in unlisted shares offers several advantages for investors. Here are some key benefits:

Potential for Higher Returns: Unlisted shares have the potential to generate higher returns compared to traditional investments. As companies grow and achieve milestones, the value of their unlisted shares can be appreciated significantly.

Early Access to Growth Opportunities: Investing in unlisted shares allows investors to access growth opportunities before they become available in the public market. This early access can provide a competitive advantage and potentially result in higher returns.

Diversification: Including unlisted shares in your investment portfolio can enhance diversification. Unlisted shares have a low correlation with traditional asset classes, such as stocks and bonds, which can help reduce overall portfolio risk.

Long-Term Investment: Investing in unlisted shares requires a long-term perspective. These investments are best suited for investors who can withstand short-term volatility and are willing to hold their positions for an extended period.

How to Invest in Tata Capital Unlisted Shares

Investing in Tata Capital unlisted shares can be done through various channels. Here are some common methods:

Private Placement: Tata Capital may offer private placements to select investors. Private placements are offerings of securities that are not registered with the Securities and Exchange Board of India (SEBI). Investors can directly subscribe to these private placements to acquire Tata Capital unlisted shares.

Secondary Market Transactions: Investors can also explore the secondary market for Tata Capital unlisted shares. This involves buying shares from existing shareholders willing to sell their holdings. Platforms like Planify provide a marketplace for such transactions, connecting buyers and sellers of unlisted shares.

Before investing, it is advisable to consult with financial advisors or professionals who specialize in unlisted shares. They can provide guidance on the investment process, assess the risks involved, and help you make informed decisions.

Conclusion

Investing in Tata Capital unlisted shares can be a lucrative opportunity for investors seeking growth in their investment portfolio. With its strong brand reputation and association with the Tata Group, Tata Capital offers a promising avenue for long-term wealth creation.

However, it is essential to conduct thorough research, analyze the company's financial performance, and evaluate the risks before investing in unlisted shares. Seeking professional advice and diversifying your portfolio can further enhance your chances of success.

[omkarpatel]

Decongestants Market is Expected to Witness High Growth Owing to Opportunity of Rising Prevalence of Respiratory Disorders

Decongestants are medicines that relieve nasal and sinus congestion or stuffiness caused by common colds or allergies. Decongestant medications work by constricting blood vessels to reduce swelling and congestion, making it easier to breathe through the nose. Factors driving the growth of the decongestant market include rising prevalence of respiratory disorders such as common cold, cough and others along with growing cases of allergies resulting from changing environment conditions.

The global decongestant market is estimated to be valued at US$ 4,710.4 Mn in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Opportunity: Rising Prevalence of Respiratory Disorders The rising prevalence of respiratory disorders across the globe presents a huge market opportunity for decongestant manufacturers. According to the World Health Organization (WHO), respiratory diseases claim over 4 million lives each year. Moreover, chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and lung cancer are some of the major causes of death and disability worldwide. Growing pollution levels and changing climate conditions are major factors contributing to the increasing burden of respiratory diseases globally. This rising prevalence of respiratory illnesses and allergies is expected to drive the demand for decongestant medications over the forecast period, which in turn is projected to promote growth of the global decongestant market. Porter's Analysis Threat of new entrants: The decongestant market is moderately difficult to enter due to established key players and required regulatory approvals. Bargaining power of buyers: Buyers have moderate bargaining power due to availability of alternative treatment options and branded/generic products. Bargaining power of suppliers: Suppliers have low to moderate bargaining power due to availability of substitute raw materials and focus on long-term relationships with buyers. Threat of new substitutes: Substitutes like antihistamines pose moderate threat due to different mechanisms of action. Competitive rivalry: Intense due to presence of large multinational corporations focusing on new product launches and strategic partnerships. SWOT Analysis Strength: Wide product portfolio and global presence of key players. Advancements in drug delivery systems improve efficacy. Weakness: Potential side effects associated with long term usage and dependence. High R&D costs for new product developments. Opportunity: Growing prevalence of respiratory illnesses increases demand. Untapped growth potential in developing regions. Threats: Stringent regulations delays product approvals. Patent expirations increase generic competition. Key Takeaways The global decongestant market is expected to witness high growth over the forecast period aided by increasing incidence of common cold and growing pollution levels. The global Decongestant Market is estimated to be valued at US$ 4,710.4 Mn in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030. North America currently dominates the market supported by well-established healthcare infrastructure and awareness regarding OTC drugs. Europe follows owing to rising respiratory ailments. Asia Pacific is projected to exhibit the fastest growth in the coming years attributed to expanding patient pool, improving access to healthcare facilities and rising disposable incomes in countries like China, India. Key players operating in the decongestant market are Johnson & Johnson, Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Sanofi S.A., Bayer AG, Reckitt Benckiser Group plc, Prestige Consumer Healthcare Inc., Procter & Gamble Co. Companies focus on joint ventures, mergers and new product launches catering to unmet needs to strengthen market position.

[industryforecastnews]

U.S. Pharmacy Market Size To Reach $708.9 Billion By 2030

U.S. pharmacy Market Growth & Trends

The U.S. pharmacy market size is expected to reach USD 708.9 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 3.67% from 2023 to 2030. This growth can be attributed to several factors, including the increasing prevalence of chronic diseases, the aging population, and expanding healthcare coverage, which leads to a higher demand for healthcare services and medications. This expansion of healthcare coverage is expected to provide more people with access to necessary medications.

In addition to these factors, the market players are introducing improved services and transitioning towards e-pharmacy, which is expected to contribute to market growth in the U.S. For instance, in February 2022, Medicure Inc. launched its Marley drug pharmacy, which is a direct-to-consumer e-commerce pharmacy platform. The platform offers over 100 chronic care medications and free delivery to any location in the U.S. and some territories. These developments are anticipated to have a positive impact on market growth.

Furthermore, the number of pharmacies in the country for drug distribution is increasing due to the rapid growth in the number of prescriptions, which is expected to have a positive impact on market growth. The National Council for Prescription Drug Programs (NCPDP) reported that the number of independent pharmacies in the U.S. increased by 12.9% from 2010 to 2019. In 2010, there were 20,427 independent pharmacies in the U.S., while in 2019, there were 23,061. This increase in the number of independent pharmacies is expected to contribute to the growth of the U.S. pharmacy industry.

Request a free sample copy or view the report summary: https://www.grandviewresearch.com/industry-analysis/us-pharmacy-market-report

U.S. Pharmacy Market Report Highlights

Based on type, the retail pharmacy segment held the largest market share in 2022 owing to easy accessibility and the presence of multiple retail pharmacy chains across the country

Based on product type, the prescription segment held the largest revenue share in 2022, owing to the increasing burden of chronic diseases and the growing aging population

Based on the ownership, the pharmacy chains segment held the largest market share in 2022 owing to the emergence of large hospital and corporation chains that offer convenient and cost-effective services, including specialty drugs, mail-order prescriptions, and other services

The market has witnessed significant vertical and horizontal consolidations in recent years, which is expected to improve services

The market potential is driving a number of service providers to strengthen their market presence by opening new centers and entering into partnerships. For instance, in October 2021, Walgreens Boots Alliance (WBA) announced an investment of USD 5.2 billion in VillageMD, a primary care provider. The investment allow VillageMD to open 600 new primary care practices in over 30 US markets by 2025, more than half of which will be located in underserved communities

U.S. Pharmacy Market Segmentation

Grand View Research has segmented the U.S. pharmacy market based on pharmacy type, product type, and ownership:

U.S. Pharmacy Type Outlook (Revenue, USD Billion, 2018 - 2030)

Hospital Pharmacy

Retail Pharmacy

ePharmacy

Others

U.S. Pharmacy Ownership Outlook (Revenue, USD Billion, 2018 - 2030)

Independent

Chain

U.S. Pharmacy Product Type Outlook (Revenue, USD Billion, 2018 - 2030)

Prescription

OTC

List of Key Players in the U.S. Pharmacy Market

CVS Health

Walgreens Boots Alliance, Inc.

Walmart Stores, Inc

Cigna Healthcare

Rite Aid Corp

The Kroger Company

Albertsons Companies, Inc

UnitedHealth Group (OptumRx)

Cardinal Health, Inc

Humana pharmacy solution

Browse Full Report: https://www.grandviewresearch.com/industry-analysis/us-pharmacy-market-report

[fin0123]

Navigating Commodity Trading Laws: Your Simple Guide 

Understanding the Basics and Rules of Commodity Trading 

Introduction: 

Commodity trading is a big part of how countries trade essential goods. It's like a marketplace for things we need. But there are many rules that can be confusing for traders. In this blog, we'll break down the complicated rules around commodity trading. We'll look at the important regulations traders must follow for a successful and legal trading experience. 

Understanding the Basics: 

Commodity trading is all about buying and selling raw materials or basic farm products, known as commodities. These can be things like oil, natural gas, wheat, or soybeans. Because these markets are global, there need to be strong rules to make sure everyone plays fair, the market is honest, and investors are protected.   

Key Rules: 

1. Commodity Exchange Act (CEA): In the U.S., there's a set of rules called the Commodity Exchange Act (CEA). The Commodity Futures Trading Commission (CFTC) enforces these rules. They control the trading of commodity futures and options, giving guidelines to traders. The aim is to make sure the market is fair, stopping fraud and tricks.   

2. Dodd-Frank Wall Street Reform and Consumer Protection Act: After the big money crisis in 2008, a law called the Dodd-Frank Act was made. It changed a lot in finance, including how commodities are traded. One important part is keeping a closer eye on special trades called over-the-counter (OTC) derivatives. This is to make things more clear and reduce big risks. 

  3. International Rules: Since commodity trading happens worldwide, there are global rules too. Groups like the International Organization of Securities Commissions (IOSCO) help make rules that everyone can agree on. This is to keep things fair and similar across different countries. 

  4. Anti-Money Laundering (AML) and Know Your Customer (KYC) Rules: Because there's a chance of bad activities in commodity trading, there are rules to stop money-related crimes (AML) and to know more about who's involved (KYC). Traders and companies need strong plans to check and confirm their clients. This is to stop money crimes and keep the market honest.   

5. Position Limits: To stop cheating and keep the market fair, authorities often make rules about how much traders can own of certain things. These rules, called position limits, set a maximum amount for traders. This helps to stop market tricks.   

Practical Tips for Following the Rules: 

1. Stay Updated: Keep an eye on news from rule-making groups and know what's changing in commodity trading rules. 

  2. Follow Strong Rules: Make good plans that follow AML, KYC, and other rules. Check regularly to make sure everything is still following the plans. 

  3. Ask for Legal Help: Because commodity trading rules are tricky, it helps to ask experts in law for help. They can give advice on following the rules and help with any legal problems. 

  4. Use Technology: Use new tools to make following rules easier. This is especially important for things like watching trades and reporting them.   

In Conclusion: 

Doing well in commodity trading means understanding the rules that control it. Traders need to be careful, keep up with changes, and have good plans to follow the rules. Staying informed and getting help from legal experts can make it easier to deal with the complex world of commodity trading rules. 

[dailystraitsdotcom]

Agape ATP Joins Nasdaq

Agape ATP Corporation Successfully Transitions to Nasdaq Stock Exchange. Read more here:

Kuala Lumpur, Oct 17: Agape ATP Corporation, a prominent player in Malaysia’s sustainable health and wellness sector, proudly announced its successful transition from the Over the Counter (OTC) market to the Nasdaq stock exchange. The Company’s new trading symbol is “ATPC,” signifying a remarkable step forward in its strategic growth and global aspirations, joining a select group of Malaysian…